DK1339678T3 - Selektive agonister til EP4-receptor til behandling af osteoporose - Google Patents

Selektive agonister til EP4-receptor til behandling af osteoporose

Info

Publication number
DK1339678T3
DK1339678T3 DK01978757T DK01978757T DK1339678T3 DK 1339678 T3 DK1339678 T3 DK 1339678T3 DK 01978757 T DK01978757 T DK 01978757T DK 01978757 T DK01978757 T DK 01978757T DK 1339678 T3 DK1339678 T3 DK 1339678T3
Authority
DK
Denmark
Prior art keywords
osteoporosis
receptor
treatment
selective agonists
agonists
Prior art date
Application number
DK01978757T
Other languages
Danish (da)
English (en)
Inventor
K Keefe Cameron
Bruce A Lefker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1339678T3 publication Critical patent/DK1339678T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK01978757T 2000-11-27 2001-11-05 Selektive agonister til EP4-receptor til behandling af osteoporose DK1339678T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27
PCT/IB2001/002073 WO2002042268A2 (en) 2000-11-27 2001-11-05 Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
DK1339678T3 true DK1339678T3 (da) 2008-02-04

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01978757T DK1339678T3 (da) 2000-11-27 2001-11-05 Selektive agonister til EP4-receptor til behandling af osteoporose

Country Status (41)

Country Link
US (3) US6552067B2 (pt)
EP (1) EP1339678B1 (pt)
JP (2) JP3984164B2 (pt)
KR (1) KR20030053063A (pt)
CN (1) CN1476429A (pt)
AR (1) AR035074A1 (pt)
AT (1) ATE374182T1 (pt)
AU (1) AU2002210848A1 (pt)
BG (1) BG107697A (pt)
BR (1) BR0115687A (pt)
CA (1) CA2429850C (pt)
CY (1) CY1106976T1 (pt)
CZ (1) CZ20031257A3 (pt)
DE (1) DE60130675T2 (pt)
DK (1) DK1339678T3 (pt)
EA (1) EA200300379A1 (pt)
EC (1) ECSP034623A (pt)
EE (1) EE200300246A (pt)
ES (1) ES2291361T3 (pt)
GT (2) GT200100238AA (pt)
HN (1) HN2001000266A (pt)
HU (1) HUP0400807A2 (pt)
IL (1) IL155368A0 (pt)
IS (1) IS6775A (pt)
MA (1) MA26961A1 (pt)
MX (1) MXPA03004623A (pt)
NO (1) NO20032360L (pt)
NZ (1) NZ525164A (pt)
OA (1) OA12533A (pt)
PA (1) PA8533901A1 (pt)
PE (1) PE20020637A1 (pt)
PL (1) PL362030A1 (pt)
PT (1) PT1339678E (pt)
SI (1) SI1339678T1 (pt)
SK (1) SK5562003A3 (pt)
SV (1) SV2003000746A (pt)
TN (1) TNSN01166A1 (pt)
TW (1) TW200424170A (pt)
UY (1) UY27038A1 (pt)
WO (1) WO2002042268A2 (pt)
ZA (1) ZA200302803B (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK5562003A3 (en) * 2000-11-27 2004-08-03 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
KR20040015364A (ko) * 2001-07-16 2004-02-18 에프. 호프만-라 로슈 아게 Ｅｐ4 수용체 작용물질로서의 프로스타글란딘 유사체
DK1408961T3 (da) * 2001-07-16 2007-11-05 Hoffmann La Roche 2 pyrrolidon-derivater som prostanoide agonister
IL159996A0 (en) * 2001-07-23 2004-06-20 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
WO2003074483A1 (fr) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
BR0308738A (pt) * 2002-03-18 2005-01-11
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (en) * 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactams as prostaglandin agonists and use thereof
JP2005534653A (ja) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
AU2003233729B2 (en) * 2002-06-06 2007-10-04 Merck Frosst Canada Ltd 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
AU2003275838A1 (en) * 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
JP2006510742A (ja) 2002-11-08 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼科組成物
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CN1735597A (zh) * 2003-01-10 2006-02-15 霍夫曼-拉罗奇有限公司 作为前列腺素激动剂的2－哌啶酮衍生物
WO2004065365A1 (ja) * 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. ８−アザプロスタグランジン誘導体およびその医薬用途
CA2513652A1 (en) 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
JP2006528154A (ja) 2003-07-18 2006-12-14 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ プロスタグランジン受容体のモジュレータとしてのヒドラジド誘導体
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
JP2007504228A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼組成物
WO2005026128A1 (en) 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
EP1663221A4 (en) 2003-09-04 2009-04-22 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005060946A1 (en) * 2003-12-17 2005-07-07 Pfizer Products Inc. Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
JP2008507521A (ja) 2004-07-20 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼科用組成物
JP4893999B2 (ja) 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
WO2006052630A1 (en) * 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
AU2005304764B2 (en) * 2004-11-08 2012-07-12 Allergan, Inc. Substituted pyrrolidone compounds as EP4 agonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
WO2006080323A1 (ja) * 2005-01-27 2006-08-03 Asahi Kasei Pharma Corporation ヘテロ６員環化合物及びその用途
ATE515263T1 (de) * 2005-05-06 2011-07-15 Allergan Inc Substituierte beta-lactame und deren verwendung in der medizin
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
EP2120962A1 (en) 2006-12-18 2009-11-25 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
CN101686985A (zh) 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
PL2155733T3 (pl) * 2007-05-23 2013-02-28 Allergan Inc Cykliczne laktamy do leczenia jaskry lub podwyższonego ciśnienia śródgałkowego
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
CA2733247C (en) * 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
WO2011047048A1 (en) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
DK2545917T3 (en) * 2010-03-08 2016-11-14 Kaken Pharma Co Ltd NEW EP4 AGONIST.
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
EP2675491A2 (en) 2011-02-17 2013-12-25 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (en) 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814482A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (en) 2012-02-16 2016-11-02 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2014015247A1 (en) * 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
EP3235817B1 (en) * 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
AU2014229065B2 (en) 2013-03-15 2017-03-09 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
AU2014290512A1 (en) * 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
WO2015056504A1 (ja) 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
WO2015188152A1 (en) 2014-06-06 2015-12-10 Allergan, Inc. Novel ep4 agonists as therapeutic compounds
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
AU2018396402C1 (en) 2017-12-25 2021-03-18 Asahi Kasei Pharma Corporation Nitrogen-containing 6-membered cyclic compound
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
SE423813B (sv) * 1976-08-06 1982-06-07 Pfizer Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) * 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (pt) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
TW420669B (en) 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
EP1121133A1 (en) * 1998-10-15 2001-08-08 Merck & Co., Inc. Methods for stimulating bone formation
AU1444200A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
WO2001046140A1 (en) * 1999-12-22 2001-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
ATE327751T1 (de) * 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
SK5562003A3 (en) * 2000-11-27 2004-08-03 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
EA200300379A1 (ru) 2003-08-28
PA8533901A1 (es) 2002-11-28
CZ20031257A3 (cs) 2004-04-14
PT1339678E (pt) 2007-11-30
ATE374182T1 (de) 2007-10-15
HUP0400807A2 (hu) 2004-07-28
UY27038A1 (es) 2002-07-31
TW200424170A (en) 2004-11-16
CA2429850C (en) 2008-12-30
CA2429850A1 (en) 2002-05-30
DE60130675D1 (de) 2007-11-08
CY1106976T1 (el) 2012-09-26
EE200300246A (et) 2003-10-15
IS6775A (is) 2003-04-10
SI1339678T1 (sl) 2007-12-31
EP1339678A2 (en) 2003-09-03
US6747054B2 (en) 2004-06-08
NZ525164A (en) 2005-04-29
GT200100238AA (es) 2004-05-12
AU2002210848A1 (en) 2002-06-03
PL362030A1 (en) 2004-10-18
US7192979B2 (en) 2007-03-20
SV2003000746A (es) 2003-01-13
SK5562003A3 (en) 2004-08-03
JP3984164B2 (ja) 2007-10-03
JP2004521869A (ja) 2004-07-22
OA12533A (en) 2006-06-05
BR0115687A (pt) 2003-09-09
NO20032360D0 (no) 2003-05-26
ECSP034623A (es) 2003-07-25
US6552067B2 (en) 2003-04-22
KR20030053063A (ko) 2003-06-27
WO2002042268A3 (en) 2002-07-25
JP2007197467A (ja) 2007-08-09
DE60130675T2 (de) 2008-01-24
US20020065308A1 (en) 2002-05-30
ES2291361T3 (es) 2008-03-01
TNSN01166A1 (fr) 2005-11-10
MA26961A1 (fr) 2004-12-20
ZA200302803B (en) 2004-04-13
NO20032360L (no) 2003-07-23
EP1339678B1 (en) 2007-09-26
US20030149086A1 (en) 2003-08-07
IL155368A0 (en) 2003-11-23
US20040259921A1 (en) 2004-12-23
HN2001000266A (es) 2002-01-30
WO2002042268A2 (en) 2002-05-30
GT200100238A (es) 2002-06-26
MXPA03004623A (es) 2003-09-05
AR035074A1 (es) 2004-04-14
BG107697A (en) 2004-01-30
PE20020637A1 (es) 2002-07-18
CN1476429A (zh) 2004-02-18

Similar Documents

Publication Publication Date Title
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
CY2017020I2 (el) Στεροειδη ως αγωνιστες για τους υποδοχεις fxr
IS6785A (is) EP4 viðtakahindrar til meðhöndlunar á liðagigt
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
NO20023672D0 (no) Sammensetninger for kontrollert frigivelse
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1553929T3 (da) Sammensætning med kontrolleret frigivelse.
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1200073T3 (da) Selektive iGluR5-receptorantagonister til behandling af migræne
DK1201655T3 (da) Fremgangsmåde til fremstilling af non-steroide glucocorticoidreceptormodulatorer
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1142477T3 (da) Sammensætninger med reguleret frigivelse
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1225878T3 (da) RAR-gamma-selektive retinoidagonister til behandling af emfysem
ITMI20001699A0 (it) Agente coesivizzante inorganico per impasti cementizi autocompattanti
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1309607T3 (da) Fremgangsmåde til fremstilling af LHRH-antagonister
DK1281707T3 (da) Fremgangsmåde til fremstilling af 5-substituerede isobenzenfuraner
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne
ITMO20030065A0 (it) Dispositivo per l'ancoraggio di lastre ceramiche.
NO20022142L (no) Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
ES1049390Y (es) Dispositivo de anclaje para encofrados de hormigon.
DK1099490T3 (da) Indretning til afkapning af rør
ID30106A (id) Pelarutan enzimatik modulator-modulator reseptor estrogen selektif